Advanced Non-small Cell Lung Cancer Patients With EGFR-TKI Research In Long-term Survival After Treatment

ObjectiveTo investigate the factors that influence the long-term survival of patients with advanced non-small cell lung cancer(NSCLC) who were treated with epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor. And detect the EGFR mutations of these long-term survival patients.MethodsFrom December2002to June2007,292patients with advanced NSCLC were enrolled for treatment with EGFR-TKI in Peking Union Medical College Hospital. Clinical data was analyzed by Pearson’s Chi-square test. Detect the EGFR mutations of the living patients in the serum samples by DNA sequencing method.ResultsThe long-term survival of EGFR-TKI-treated patients had a3-year survival rate of16.1%, which was correlated with smoking history (P=0.033), and pathological type(P=0.006). It was not correlated with gender(P=0.311), age(P=0.121), ECOG score(P=0.299), and clinical stage(P=0.235). EGFR sensitive mutation rate in the serum of long-term survival patients was65.2%, and the mutation rates of female patients (68.8%) and adenocarcinoma patients were higher than the others.ConclusionsEGFR-TKI offers a new treatment option for advanced NSCLC. EGFR mutation status may have important significance for evaluating the prognosis of advance NSCLC patients treated with EGFR-TKI.